Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Mar 25, 2013 4:39pm
329 Views
Post# 21165281

RE: website update...

RE: website update...

Thanks Kelsee for noticing the updated events page. It looks like the ATVB conference May 1-3 and the Epigentics Conference May 8-10 are great candidate time frames for the big ASSURE results announcement. Very likely RVX will make the ASSURE trial completion sometime in April, as SanFran discussed on the board earlier. So I'm anticipating 2 solid and a third potential catalysts: 1) ASSURE completion early/mid April, 2) Potential ASSURE topline data announcment mid to late April, and 3) ASSURE official results in early May at ATVB or Epigenetics conference. Of course SUSTAIN publication might be in the mix here somewhere too, but not as big of a deal anymore with ASSURE results pending.

Bullboard Posts